UBAP2 (F6E7I) Rabbit mAb #64790
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 140 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
In hepatocellular carcinoma (HCC) tissues, UBAP2 is downregulated, and higher UBAP2 expression levels in these tissues are associated with a better prognosis, making UBAP2 a novel biomarker for prognostic prediction (4). When UBAP2 forms a complex with annexin A2, it promotes the degradation of annexin A2 protein through ubiquitination, thereby inhibiting HCC progression (4). Circular RNA UBAP2 (circUBAP2) has been shown to promote the progression of several cancers, including osteosarcoma, ovarian, prostate, and cervical cancer (5-8). UBAP2 is also associated with osteoporosis, acting as a potential biomarker and therapeutic target (9).
- Herlihy, A.E. et al. (2022) DNA Repair (Amst) 115, 103343.
- Reese, J.C. (2023) Biochim Biophys Acta Gene Regul Mech 1866, 194956.
- Muñoz, J.C. et al. (2022) Genes (Basel) 13, 1951. doi: 10.3390/genes13111951.
- Bai, D.S. et al. (2016) Oncotarget 7, 32946-55.
- Zhang, H. et al. (2017) Oncotarget 8, 61687-61697.
- Li, X. et al. (2021) Oncol Lett 21, 486.
- Xu, Q. et al. (2020) J Ovarian Res 13, 81.
- Meng, L. et al. (2020) Cancer Cell Int 20, 357.
- Kim, J. et al. (2023) Nat Commun 14, 3668.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.